Concern Rises Over $475,000 Price Tag for Breakthrough Cancer Treatment

The immunotherapy drug Kymriah from Novartis has been hailed as a breakthrough in cancer treatment. But is its cost justified?

Copyright Disclaimer:This article has been RSS syndicated and was originally published here.